Skip to main content

Day: February 13, 2025

Microbix Reports Strong Revenues & Earnings for Q1 Fiscal 2025

Quarterly Revenues of $6.0 million and Net Income of $0.9 million MISSISSAUGA, Ontario, Feb. 13, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”). Results for Q1 demonstrated the results of ongoing efforts to increase recurring sales of Microbix’s diagnostic-test related ingredients and devices businesses, work that resulted in a 40% year-over-year increase in such revenues and material net income for the quarter. Management DiscussionResults for Q1 show robust growth in recurring sales of Microbix’s test ingredients (“Antigens”) and test quality assessment products (“QAPs™”), which exceeded C$ 6.0 million (collectively up by 40% for Q1 versus prior...

Continue reading

Calian Reports Results for the First Quarter

(All amounts in release are in Canadian dollars) OTTAWA, Ontario, Feb. 13, 2025 (GLOBE NEWSWIRE) — Calian® Group Ltd. (TSX:CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions, today released its results for the first quarter ended December 31, 2024. Q1-25 Highlights:Revenue up 3% to $185 million Gross margin at 31.8%, slightly down from 32.5% last year Adjusted EBITDA1 of $18 million, down from $21 million last year Operating free cash flow1 of $13 million, down from $17 million last year Net debt to adjusted EBITDA1 ratio of 0.6x Repurchased 101,350 shares in consideration of $4.9 million Guidance reiterated Announced new U.S. subsidiary to focus on U.S. government and defence   Financial Highlights Three months ended(in millions of $,...

Continue reading

Brookfield Corporation Reports Record 2024 Results

Distributable Earnings Before Realizations Increased 15% to a Record $4.9 billion or $3.07 Per Share Quarterly Dividend Raised by 13% BROOKFIELD, NEWS, Feb. 13, 2025 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) announced record financial results for the year ended December 31, 2024. Nick Goodman, President of Brookfield Corporation, said, “We delivered record financial results in 2024, with strong contributions from each of our businesses. Our asset management business had inflows of over $135 billion, our wealth solutions business is now firmly established as a top-tier annuity writer in the U.S., and our operating businesses continue to generate high-quality and stable cash flows.” He continued, “We expect the positive momentum in each of our businesses to continue this year. Our access to scale capital remains...

Continue reading

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $1.5 Billion as of December 31, 2024 – CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK)...

Continue reading

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

–Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function– — The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed– –Topline results of the Phase 2b extension maintenance study to reduce fat regain following discontinuation of GLP-1 RA are expected in the second quarter of calendar 2025– –Company announces new cardiometabolic indication for sabizabulin to treat inflammation in atherosclerotic coronary artery disease– –Company sold the FC2 Female Condom®...

Continue reading

Abaxx Will Expand Battery Metals Product Suite with Launch of Lithium Carbonate Futures on March 7, 2025

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, indirect majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced that it will be expanding its battery metals product suite with the launch of 3 regional physically-deliverable Lithium Carbonate futures on March 7, 2025. Abaxx Lithium Carbonate futures mark a significant development as the world’s first physically deliverable lithium carbonate contracts priced in US dollars. These new contracts provide market participants with standardized and globally accessible pricing...

Continue reading

Prime Drink Group Announces Its Intention to Unlock the Value of Its Quebec Water Assets

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce its intention to unlock the value of its water assets. The Company is one of the largest holders of water rights in Quebec with a total volume of 3.4 billion litres per year. Over the past week, Olivier Primeau, Prime’s Chief Brand and Innovation Officer, made a reconnaissance trip to Quebec City to discuss his vision for the future of water, a primary resource in Quebec, with ministers from the various provincial parties. “When our investment group first invested in Prime, it was primarily for its water assets,” said Mr. Primeau. “In today’s uncertain economic climate, every project capable of generating revenue for Quebec is more important than ever. We must learn to make better use of our...

Continue reading

Kelly Reports Fourth-Quarter and Full-Year 2024 Earnings

TROY, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) —  Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced fourth-quarter and full-year 2024 earnings.Q4 revenue of $1.2 billion, down 3.3% year-over-year reflecting the previously disclosed dispositions and acquisitions, and up 4.4% on an organic basis. Full-year revenue of $4.3 billion, down 10.4% as reported and up 0.5% on an organic basis. Q4 operating loss of $56.7 million on $80.8 million non-cash impairment charges; $29.2 million of operating income on an adjusted basis, up 32% versus the prior year period Q4 adjusted EBITDA of $43.5 million, up 34% versus the prior year; adjusted EBITDA margin increased 110 basis points versus the prior year period to 3.7% Full-year operating loss of $15.1 million resulting from non-cash impairment charges;...

Continue reading

Twelve Capital and Securis complete merger to create a leader in Insurance-Linked Securities (ILS)

Combined firm positioned as global independent investment manager in Insurance-Linked Securities (ILS), with USD 8.5 billion in assets under management ZURICH and LONDON, Feb. 13, 2025 (GLOBE NEWSWIRE) — Twelve Capital and Securis Investment Partners have completed the final steps of the merger, establishing Twelve Securis as a global leader in the field of Insurance-Linked Securities (ILS). This strategic move unites a wealth of expertise, complementary skill sets, and a shared dedication to innovation in insurance investment. With USD 8.5 billion in assets under management, Twelve Securis is strategically positioned to expand investment opportunities in catastrophe bonds, private ILS, and broader insurance markets. With a strong focus on performance generation under rigid investment governance, the firm will continue to pioneer...

Continue reading

Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. ORLANDO, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa™ Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.